Back to Directory

Ecallantide

Performance & Endurance

Kallikrein inhibitor for hereditary angioedema, prevents bradykinin formation.

Key Benefits

  • ✓Treats HAE attacks
  • ✓Prevents bradykinin formation
  • ✓Reduces swelling
  • ✓Alternative to icatibant

Dosing Information

Dosage Range
10 mg x 3 injections
Frequency
During HAE attack
Typical Duration
As needed

Detailed Protocol

Administered via subcutaneous injection by healthcare professional only. Three injections (total 30mg) given during HAE attack. Must be given in medical setting due to anaphylaxis risk.

About Ecallantide

Ecallantide (Kalbitor) is a recombinant 60-amino acid protein that inhibits plasma kallikrein, preventing the conversion of kininogen to bradykinin. FDA-approved for acute HAE attacks. Administered by healthcare professionals due to anaphylaxis risk.

Research Notes

FDA-approved in 2009 for HAE. Effective for acute attacks but requires medical administration due to anaphylaxis risk. Black box warning for hypersensitivity.

Get Peptide Research Updates

Newsletter signup

Please wait...

Thanks for signing up! You will receive an email to confirm your subscription.

Potential Side Effects

  • •Anaphylaxis risk (4%)
  • •Injection site reactions
  • •Headache
  • •Nausea
  • •Must be given by healthcare provider

Always consult with a healthcare professional before starting any peptide therapy.